U.S. markets closed

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9300-0.0800 (-2.66%)
At close: 04:00PM EDT
3.0100 +0.08 (+2.73%)
After hours: 06:36PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close3.0100
Bid2.7500 x 900
Ask3.0200 x 800
Day's Range2.8300 - 3.0100
52 Week Range2.5200 - 4.4600
Avg. Volume58,119
Market Cap106.905M
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-0.6370
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BCLI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Brainstorm Cell Therapeutics In
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • PR Newswire

    BrainStorm to Announce Second Quarter Results and Provide a Corporate Update

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, August 15, 2022.

  • PR Newswire

    BrainStorm Announces Presentations at June 2022 Scientific Conferences

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at forthcoming ALS and MS scientific conferences in June 2022. Insights into the ALS Phase 3 primary endpoint leveraging ENCALS model patient prognosis trajectories will be presented as a scientific poster at the European Network to Cure ALS (ENCALS) meeting in Edinburgh, Scotland June 1-3, 2022. At the Consortium of Multiple Sclerosis Centers

  • Zacks Small Cap Research

    BCLI: Anticipating News on How NurOwn® Will be Advanced Forward…

    By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Anticipating News on How NurOwn® Will be Advanced Forward in ALS BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is developing NurOwn as a treatment for patients with amyotrophic lateral sclerosis (ALS). The company recently published results from the Phase 3 trial of NurOwn in Muscle and Nerve that showed while